Antenatal herpes serologic screening: An appraisal of the evidence

Obstetrics and Gynecology

Volumn 108, Issue 5, 2006, Pages 1247-1253

  Tita, Alan T N ^a   Grobman, William A ^b   Rouse, Dwight J ^b  

^a Division of Maternal Fetal Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH PROGRAM; HEPATITIS B VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INTERMETHOD COMPARISON; MEDICAL LITERATURE; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SCREENING TEST; SYSTEMATIC REVIEW;

COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HUMANS; INFANT, NEWBORN; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; SIMPLEXVIRUS;

EID: 33750521786     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000236433.29679.9a     Document Type: Article

References (49)

1. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1-78.
2. Flemming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus type 2 in the United States, 1976-1994. N Engl J Med 1997;337:1105-11.
3. Cowan FM, Copas A, Johnson AM, Ashley R, Corey L, Mindel A. Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence? Sex Transm Infect 2002;78:346-8.
4. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, et al. Acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509-15.
5. Schillinger JA, Xu F, Sternberg MR, Armstrong GL, Lee FK, Nahmlas AJ, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 2004;31:753-60.
6. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003;30:797-800.
7. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-9.
8. Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev 2004;17:1-13.
9. Tookey P, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol 1996;10:432-42.
10. American College of Obstetricians and Gynecologists. Management of herpes in pregnancy: clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 2000;68:165-73.
11. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2: Chiron HSV Vaccine Study Group. N Engl J Med 1999;341:1432-8.
12. Gardella C, Brown Z, Wald A, Selke S, Zeh J, Morrow RA, et al. Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol 2005;193:1891-9.
13. Brown ZA, Gardella C, Wald A, Morrow RA, Corey L. Genital herpes complicating pregnancy. Obstet Gynecol 2005;106:845-56.
14. Baker DA. Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol 2005;193:1887-8.
15. Peters TJ, Wildschut HIJ, Weiner CP. Epidemiologic considerations in screening. In: Wildschut, HIJ, Weiner CP, Peters TJ, eds. When to screen in obstetrics and gynecology. Philadelphia (PA): WB Saunders. 2006 p 1-14.
16. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002;359:881-4.
17. Rouse DJ, Stringer JS. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. Am J Obstet Gynecol 2000;183:400-6.
18. Barnabas RV, Carabin H, Garnett GP. The potential role of suppressive therapy for sex partners in the prevention of neonatal herpes: a health economic analysis. Sex Transm Infect 2002;78:425-9.
19. Baker D, Brown Z, Hollier LM, Wendel GD Jr, Hulme L, Griffiths DA, et al. Cost-effectiveness of herpes simplex virus type 2 serologic testing and antiviral therapy in pregnancy. Am J Obstet Gynecol 2004;191:2074-84.
20. Thung SF, Grobman WA. The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies. Am J Obstet Gynecol 2005;192:483-8.
21. Cleary KL, Pare E, Stamilio D, Macones GA. Type-specific screening for asymptomatic herpes infection in pregnancy: a decision analysis. BJOG 2005;112:731-6.
22. Chuang TY. Neonatal herpes: incidence, prevention, and consequences. Am J Prev Med 1988;4:47-53.
23. Whitley RJ. Neonatal herpes simplex virus infections. J Med Virol 1993;Suppl 1:13-21.
24. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. Engl J Med 1991;324:444-9.
25. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Engl J Med 1991;324:450-4.
26. Chou R, Smits AK, Huffman LH, Fu R, Korthuis PT. Prenatal screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2005;143:38-54.
27. Centers for Disease Control (CDC). Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR Morb Mortal Wkly Rep 1988;37:341-6, 351.
28. Kinghorn GR. Debate: the argument for. Should all pregnant women be offered type-specific serological screening for HSV infection? Herpes 2002;9:46-7.
29. Arvin AM. Debate: the argument against. Should all pregnant women be offered type-specific serological screening for HSV infection? Herpes 2002;9:48-50.
30. Taboulet F, Halioua B, Malkin JE. Quality of life and use of health care among people with genital herpes in France. Acta Derm Venereol 1999;79:380-4.
31. Melville J, Sniffen S, Crosby R, Salazar L, Whittington W, Dithmer-Schreck D, et al. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sex Transm Infect 2003 Aug;79:280-5.
32. American College of Obstetricians and Gynecologists. Viral hepatitis in pregnancy. Int J Gynaecol Obstet 1998;63:195-202.
33. Ashley RL. Performance and use of HSV type-specific serology test kits. Herpes 2002;9:38-45.
34. Patel R. Educational interventions and the prevention of herpes simplex virus transmission. Herpes 2004;11 (Suppl):155A-160A.
35. Orr DP, Langefeld CD, Katz BP, Caine VA. Behavioral intervention to increase condom use among high-risk female adolescents. J Pediatr 1996;128:288-95.
36. Boyer CB, Barrett DC, Peterman TA, Bolan G. Sexually transmitted disease (STD) and HIV risk in heterosexual adults attending a public STD clinic: evaluation of a randomized controlled behavioral risk-reduction intervention trial. AIDS 1997;11:359-67.
37. Shain RN, Piper JM, Newton ER, Perdue ST, Ramos R, Champion JD, et al. A randomized, controlled trial of a behavioral intervention to prevent sexually transmitted disease among minority women. N Engl J Med 1999;340:93-100.
38. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Bolam G, Zenilman J, et al Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998;280:1161-7.
39. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-6.
40. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.
41. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Grubber WC, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001;108:230-8.
42. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003;325:349-362.
43. Friedberg M, Saffran B, Stinson TJ, Neslon W, Bennett CL. Evaluation of conflict of interest in economic analysis of new drugs used in oncology. JAMA 1999;282: 1453-7.
44. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Defic Syndr 2000;25:403-16.
45. Gorsky RD, Farnham PG, Straus WL, Caldwell B, Holtgrave DR, Simonds RJ, et al. Preventing perinatal transmission of HIV-costs and effectiveness of a recommended intervention. Public Health Rep 1996;111:335-41.
46. Lewis R, O'Brien JM, Ray DT, Sibai BM. The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Am J Obstet Gynecol 1995;173:1329-33.
47. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus [published erratum appears in JAMA 1988;260:478]. JAMA 1988;259:365-9.
48. Royal College of Obstetricians and Gynaecologists. Management of genital herpes in pregnancy. Clinical guideline No. 30. RCOG 2002.
49. Glass N, Nelson HD, Huffman L. Screening for genital herpes simplex: brief update. AHRQ Publication N. 05-0573-B. March 2005. Rockville (MD): Agency for Health Care Research and Quality. 2005. Available at: http://www.ahrq.gov/ clinic/uspstf05/herpes/herpesup.htm. Retrieved July 25, 2006.